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Abstract 
Purpose: MicroRNAs are small non-coding RNAs that regulate gene expression, thereby playing a 
role in a variety of physiological and pathophysiological states. Exposure to cigarette smoke 
extensively downregulates microRNA expression in pulmonary cells of mice, rats, and humans. 
Cellular microRNAs are released into body fluids, but a poor parallelism was previously observed 
between lung microRNAs and circulating microRNAs. The purpose of the present study was to 
validate the application of this epigenetic biomarker by using less invasive collection procedures. 
Experimental design: Using microarray analyses, we measured 1135 microRNAs in 10 organs 
and 3 body fluids of mice that were either unexposed or exposed to mainstream cigarette smoke for 
up to 8 weeks. The results obtained with selected miRNAs were validated by qPCR. 
Results: The lung was the main target affected by smoke (190 dysregulated miRNAs), followed by 
skeletal muscle (180), liver (138), blood serum (109), kidney (96), spleen (89), stomach (36), heart 
(33), bronchoalveolar lavage fluid (32), urine (27), urinary bladder (12), colon (5), and brain (0). 
Skeletal muscle, kidney, and lung were the most important sources of smoke-altered microRNAs in 
blood serum, urine, and bronchoalveolar lavage fluid, respectively.  
Conclusions: microRNA expression analysis was able to identify target organs after just 8 weeks of 
exposure to smoke, well before the occurrence of any detectable histopathological alteration. The 
present translational study validates the use of body fluid microRNAs as biomarkers applicable to 
human biomonitoring for mechanistic studies, diagnostic purposes, preventive medicine, and 
therapeutic strategies. 
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Introduction 
microRNAs (miRNAs) are a class of 
endogenous, small (18-25 nucleotides), non-coding, 
single-stranded RNAs that modulate messenger RNA 
(mRNA) levels either by translational repression or 
post-transcriptionally induced mRNA decay. Each 
miRNA regulates up to several hundred mRNAs 
simultaneously and affects a number of target 
transcripts. These molecular biomarkers have been 
implicated in almost every biological process, 
including development, cell cycle regulation, cell 
growth and differentiation, stress response, and 
apoptosis. As such, miRNAs regulate a variety of 
physiological processes and play a role in the 









neurologic, immune-related, and other diseases [1]. In 
particular, miRNA profiles are dysregulated in 
cancers [2] by a variety of mechanisms including 
amplification, deletion, mutation, and epigenetic 
silencing [3]. Several genes encoding miRNAs have 
been characterized as novel proto-oncogenes [4]. 
 The study of cellular miRNAs requires the 
availability of target tissues, which are easily 
accessible in preclinical studies but require the use of 
biopsy material involving invasive collection 
procedures in humans. In addition, miRNAs have 
been found in a variety of body fluids, where they are 
remarkably stable [5-7]. Extracellular miRNAs could 
serve as molecular biomarkers for diagnostic 
purposes applicable to both prevention and therapy 
of human diseases. However, extensive research is 
necessary for identifying the characteristics of 
extracellular miRNAs to delineate their roles in cancer 
pathobiology and cancer prevention [5]. The main 
problem in pursuing this approach is that 
extracellular miRNAs are not very specific, being 
released from a variety of tissues either under 
physiological conditions or the effect of exogenous 
agents (diet, drugs, toxicants, protective factors, etc.) 
or the influence of pathological conditions. 
Accordingly, there may be a poor correlation between 
cellular and extracellular miRNAs and between 
miRNAs detectable in different biological fluids [8, 9]. 
 Therefore, there is need for translational studies 
aimed at assessing the suitability of extracellular 
miRNAs as a signature of tissue damage and of 
dysregulation of cellular miRNA profiles. In addition, 
application of miRNA monitoring to humans as a 
diagnostic tool for the prevention of cancer and other 
diseases implies that no pathological condition is 
clinically apparent. The goal of the present study was 
to evaluate miRNA expression in multiple mouse 
organs, including lungs, liver, heart, kidney, spleen, 
urinary bladder, skeletal muscle, colon, stomach, and 
brain, and to establish the correlation with the levels 
of extracellular miRNAs in body fluids. In humans, 
the examined fluids can be collected by means either 
of non-invasive procedures (urine), minimally 
invasive procedures (blood serum), or semi-invasive 
procedures (bronchoalveolar lavage fluid or BALF).  
Besides being the most important threat to 
human health, smoking typically targets multiple 
systems, organs, and tissues. In the oncological 
domain, according to the International Association for 
Research on Cancer (IARC), there is evidence for a 
causal association of smoking with cancers affecting 
(a) the respiratory system (nasal cavity and paranasal 
sinuses, nasopharynx, oropharynx and hypopharynx, 
larynx, and lung), (b) the urinary tract (kidney pelvis, 
ureter, and bladder), (c) the digestive system (oral 
cavity, oesophagus, stomach, colon-rectum, liver, and 
pancreas), (d) the reproductive tract (ovary and 
uterine cervix), and (e) the hematopoietic system 
(myeloid leukemia) [10]. In addition, either alone or in 
synergy with other risk factors, smoking plays 
important roles in the pathogenesis of other chronic 
degenerative diseases, including chronic obstructive 
pulmonary diseases (COPD), such as emphysema and 
chronic bronchitis, cardiovascular and cerebrovas-
cular diseases, neurodegenerative disorders, and 
reproductive effects [11]. In the present study, the 
mice were either untreated or exposed, for varying 
periods of time, to cigarette smoke (CS), in the form of 
mainstream CS (MCS). It is noteworthy that the mice 
were not exposed to selected MCS components but to 
MCS as a complex mixture of more than 5000 
identiﬁed chemical compounds [12] in order to 
reproduce the systemic spread, the multiple mechan-
isms, and the interplay between its components. 
Materials and Methods 
Study design  
Young mice were either untreated or exposed to 
MCS for up to 8 weeks. RNA was purified from 10 
organs and 3 biological fluids, and the expression of 
1135 miRNAs was evaluated by microarrays. For 
selected miRNAs, the results were validated by qPCR. 
Mice  
Two-month old Swiss ICR (CD-1) mice were 
purchased from Harlan Laboratories (San Pietro al 
Natisone, Udine, Italy). The mice were housed in 
MakrolonTM cages on sawdust bedding and 
maintained on standard rodent chow (Teklad 9607, 
Harlan Laboratories) and tap water ad libitum. The 
animal room temperature was 23 ± 2°C, with a 
relative humidity of 55% and a 12 h day-night cycle. 
Housing and treatments of mice were in accordance 
with NIH, European (2010/63 UE Directive), and 
institutional guidelines. The issuance of the NIH 
Office of Laboratory Animal Welfare (OLAW) with 
the University of Genoa bears the identification 
number A5899-01 and is effective until February 28, 
2021. The IACUC protocol was approved by the Fox 
Chase Cancer Center Committee on April 13, 2015. 
Experimental groups 
The following 8 groups of mice were used: 
Groups A, B, C, and D, mice kept in filtered air for 2, 
4, 6, and 8 weeks, respectively (sham-exposed mice); 
Groups E, F, G, and H, mice exposed to MCS for 2, 4, 
6, and 8 weeks, respectively (MCS-exposed mice). 
Groups A-C and E-G were composed of 10 females 
each, whereas Groups D and H were composed of 10 
males and 10 females each. 





Exposure to MCS 
A whole-body exposure of mice to MCS was 
achieved by using Kentucky 2R4F reference cigarettes 
(College of Agriculture, The Reference Cigarette 
Program, University of Kentucky, Lexington, KY), 
having a declared content of 9.4 mg tar, 0.73 mg 
nicotine, and delivering 12 mg of CO each when 
burned. MCS was delivered to the exposure chambers 
by drawing 15 consecutive puffs, each of 60 mL and 
lasting 6 s. Each daily session involved 6 consecutive 
exposures, lasting 10 min each, with 1 min intervals, 
during which a total air change was made. The 
average concentration of total particulate matter 
measured in the exposure chambers was 784 mg/m3. 
Collection of organs and body fluids 
At the indicated times, the mice were 
euthanized. Each mouse was transferred into a 
separate chamber and isolated from the other mice. 
The 2013 AVMA guidelines on euthanasia were 
followed using slow introduction of CO2 
asphyxiation. Death was confirmed by absence of 
respiration and/or heartbeat. Immediately after 
sacrifice, the BAL was performed by intubating the 
trachea and lavaging with 5 mL of PBS per mouse. 
The BAL samples were centrifuged and the 
supernatants (BALF) were pooled within each 
experimental group. The blood was collected by heart 
puncture and used for preparing serum. The urine 
was collected for 8 h and pooled from the mice 
belonging to each experimental group by using 
metabolic cages during the day preceding euthanasia 
of mice. The urine was centrifuged in order to remove 
the sediment. Ten organs, including lungs, liver, 
heart, kidney, spleen, urinary bladder, skeletal muscle 
(left gastrocnemius), colon, stomach, and brain, were 
collected. Immediately after collection, each organ or 
fluid was immersed in RNAlater and kept at -80°C.  
RNA extraction 
RNA was extracted individually from the 10 
organs of mice belonging to all experimental groups, 
whereas the body fluids were pooled within each 
group, irrespective of gender due to the low amounts 
of samples available. RNA was extracted from mouse 
organs (miRNeasy, Qiagen, Hilden, Germany) and 
body fluids (Exiqon’s miRCURY™ RNA Isolation Kit 
– Biofluids (Exiqon, Vedbaek, Denmark) according to 
the manufacturers’ instructions. The Qubit 
quantitation assay was used to standardize miRNA 
quantities to be processed by microarray and qPCR 
(Qubit™ 3.0 Fluorometer, Life Technologies, Gent, 
Belgium).  
Evaluation of miRNA expression analysis by 
microarray 
For evaluating the expression of miRNAs, we 
used the 7th generation miRCURY LNATM 
microRNA Array (Exiqon), which contains 3100 
capture probes covering human, mouse, and rat 
miRNAs. In particular, this microarray analyzes the 
expression of 1135 mouse miRNAs. The total RNA 
from each sample was labeled with Label IT® miRNA 
Labeling Kits, Version 2 (Mirus Bio, WI) following the 
standard protocol. Total RNA (500 ng) was mixed 
with 10 µL 10x labeling buffer, 4 µL Label IT reagent 
(containing Cy 3 or Cy 5 fluorescent tracers), and 
water to 86 µL. The samples were incubated at 36°C 
for 1 h and the reaction was stopped by adding 10 µL 
Stop Reagent. Two differently labeled samples (with 
Cy3 and Cy5, respectively) were collected together, 
purified onto a chromatographic column, and then 
eluted in 25 µL elution buffer. Then, 25 µL of 2x 
Hybridization Solution (Exiqon) was added and 
mixed thoroughly, and the resulting mixture was 
denatured at 65°C for 3 min. The labeled mix was 
transferred to the microarray and covered with 
coverslips. The hybridization was performed in 
GlassArray Hybridization Cassettes (Invitrogen Ltd, 
Paisley, UK) in a water bath at 37°C for 16 h and then 
a wash sequence was performed. The array was dried 
by centrifugation and scanned by a laser scanner 
(ScanArray, PerkinElmer, Waltham, MA) to record 
fluorescent signals produced by each spotted probe 
effectively hybridized with the corresponding 
miRNA. 
 Microarray data have been recorded in the GEO 
database (GEO accession No. GSE107962). 
Evaluation of miRNA expression analysis by 
qPCR 
Validation of microarray data was performed by 
real time-qPCR for let-7e, miR-125b, and miR-322-3p. 
SYBR GREEN fluorescent tracers were used to 
identify amplicons whose identity was checked by 
melting curve analysis. Primer sequences (TIB 
Molbiol, Genoa, Italy) were identified according to 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/d
atabase. cDNAs were prepared by using Superscript 
II Reverse Transcription kit (Invitrogen, Carlsbard, 
CA). PCR was performed in a Rotor-Gene 3000 
(Corbett Research, Mortlake, Australia). Each reaction 
was carried out using 10x PCR buffer, 50 mM MgCl2, 
dNTM mix, primerA 10 µM, primerS 10 µM, 
Platinum® Taq DNA polymerase (Invitrogen), cDNA 
(diluted 1:10), and SYBR GREEN® (Invitrogen) in a 50 
μL reaction volume. The thermal profile consisted of 
hot-start enzyme activation at 95°C for 2 min, 45 
cycles of PCR at 94°C for 45 s (denaturation), 





gene-specific temperature annealing for 30 s, and 72°C 
for 30 s (elongation). Gene expression was normalized 
to the RNU6 housekeeping gene. Each sample was 
tested in triplicate and the results were expressed as 
relative gene expression intensities as obtained from 
the first positive amplification cycle. 
Statistical analysis  
Differences in body weight gain between 
MCS-exposed and sham-exposed mice were evaluat-
ed for statistical significance by ANOVA followed by 
Student’s t test for unpaired data. miRNA microarray 
data, after local background subtraction, log 
transformation, and normalization were analyzed by 
GeneSpring software (Agilent, Santa Clara, CA). 
Expression data were median centered by using the 
GeneSpring normalization option. Comparisons 
between experimental groups were done by 
evaluating the fold variations of duplicate data 
generated for each miRNA. In addition, the statistical 
significance of the differences was evaluated by 
means of the GeneSpring ANOVA applied by using 
Bonferroni multiple testing correction. As inferred 
from volcano-plot analysis, differences between sets 
of data were taken as significant when they were 
statistically significant (P < 0.05) and showed >2-fold 
variation. The microarray data were processed by 
GeneSpring software and their overall variability, as 
related to treatments, was examined by scatter-plot 
analysis (SPA), hierarchical cluster analysis (HCA), 
and principal component analysis (PCA). MA-plots 
were calculated by using the R.Net Inferno RDN 
software (Pacific NorthWest National Lab, Richland, 
WA, USA). Due to the huge number of datasets to be 
analyzed, pooled analysis of microarray data was 
performed without taking into account intergender 
differences, a goal that was out of the scope of the 
present study and that had been evaluated in 
previous studies [9]. However, intergender 
differences were evaluated for selected miRNAs by 
using qPCR analysis. The significance of the 
differences in qPCR data between MCS-exposed and 
sham-exposed mice was evaluated by Student’s t test 
for unpaired data. 
Results 
Body weights of mice as related to exposure to 
MCS 
All mice were weighed on the 1st day of 
treatment (time 0) and thereafter at weekly intervals. 
The body weights at time 0 (mean ± SE) of 
sham-exposed mice were 38.7 ± 1.15 g for males and 
28.9 ± 0.79 g for females. Thereafter, exposure to MCS 
tended to slightly decrease the body weights, and 
from the second week onwards the differences were 
statistically significant at most time points. Thus, after 
8 weeks the body weights of sham-exposed mice were 
42.3 ± 1.09 g for males and 37.5 ± 1.16 g for females, 
and those measured of MCS-exposed mice were 39.4 ± 
0.70 g for males (P < 0.05 as compared to 
sham-exposed males) and 31.7 ± 1.22 g for females (P 
< 0.01 as compared to sham-exposed females). 
Evaluation of RNA purity 
Evaluation by nanospectrophotometry showed 
that the RNA purified from all organs was of good 
quality, as inferred from the calculation of the 260/280 
and 260/230 absorbance ratios, which were 
consistently higher than 1.9 and 1.3, respectively (data 
not shown). The RNA recovery efficiency from each 
one of the 10 organ specimens was satisfactory, 
ranging between 15.9 ± 0.6 µg for skeletal muscle to 
156.6 ± 5.5 µg for kidney. As for the body fluids 
specimens, the overall 260/280 ratio was 1.3 ± 0.04 for 
blood serum, 1.7 ± 0.3 for BALF, and 1.3 ± 0.1 for 
urine, and the amount of purified RNA was 178.0 ± 
12.0 ng for blood serum, 4.3 ± 12.0 ng for BALF, and 
95.9 ± 70.2 ng for urine. The presence of miRNAs in 
sufficient amounts to perform microarray analyses 
was further confirmed by Qubit quantitative 
fluorescence analysis, which indicated that the 
collected samples were adequate to perform 
microarrays.  
Comparison of global miRNA profiles in 
organs and body fluids of sham-exposed mice 
and MCS-exposed mice 
The overall profiles of miRNA expression, as 
evaluated by microarray analyses, were compared by 
HCA and PCA. Due to the huge amount of data, these 
analyses were carried out by pooling the results 
obtained in males and females, whereas intergender 
differences were evaluated for the miRNAs analyzed 
in parallel by microarray and qPCR (see below). HCA 
indicated that, under the basal conditions of 
sham-exposed mice (Fig. 1, left panel), body fluids 
have different miRNA expression profiles as 
compared to body organs. In fact, BALF, blood serum, 
and urine clustered together in the hierarchical tree on 
the left part of the dendrogram, separately from body 
organs. Some organs belonging to the same system, 
such as the urinary bladder and kidney, or having a 
similar histological structure, such as skeletal muscle 
and heart, clustered together or in nearby branches in 
the central part of the dendrogram. Likewise, in 
MCS-exposed mice (Fig. 1, middle panel) BALF, blood 
serum, and urine clustered together in the hierarchical 
tree on the left part of the dendrogram, separately 
from body organs. Positioning of the 10 organs in the 





dendrogram was considerably altered as compared 
with the pattern observed in sham-exposed mice. 
These patterns did not change when evaluating the 
difference between MCS and Sham values in order to 
detect the net effects of MCS (Fig. 1, right panel). 
Similar findings were obtained by PCA, which 
indicated that the miRNA profiles of body fluids were 
located close to each other but far away from most 
organs in sham-exposed mice (Fig. 2, upper panel). 
The only exception was the stomach of sham-exposed 
mice, which may contain some residual amounts of 
gastric mucus. Organs having similar tissue 
composition, i.e., skeletal muscle and heart, were 
located nearby each other in the same quadrant, 
irrespective of exposure to MCS. These results 
indicate that miRNA profiles are tissue-specific. 
Exposure of mice to MCS (Fig. 2, middle panel) 
completely modified the position of the lung miRNA 
profile, which moved from the right-upper quadrant 
to the left-bottom quadrant. Other organs changing 
PCA quadrant were the skeletal muscle, stomach, 
heart, liver, and kidney. The influence of MCS on 
body fluids was less remarkable. In fact, BALF, blood 
serum and urine merely moved their position from 
the lower limit to the upper limit of the right bottom 
quadrant. A similar picture was observed by 
calculating the differences between MCS and Sham 
values (bottom panel). 
The MCS organotropism was evaluated in detail 
by comparative scatter-plot analysis (SPA, Fig. 3). 
According to the number of miRNAs varying their 
expression more than 2-fold as a consequence of 
exposure to MCS (i.e., being located outside the 
diagonal area limited by green lines in Fig. 3), the 
preferentially hit organ by MCS was the lung, 
followed by skeletal muscle, liver, kidney, and spleen. 
An intermediate effect was detected in heart, stomach, 
and urinary bladder, and only minimal alterations of 
miRNA profiles occurred in colon and especially in 
brain. Blood serum, BALF, and urine were altered in 
their miRNA profiles in decreasing order of 
magnitude. The remarkable effect of MCS on lung, 
heart, and skeletal muscle as compared to other 
organs was also detected by MA-plots (Fig. 1S). 
The "translatability" of the results obtained to 
humans was evaluated comparing by SPA the MCS 
effect on mouse miRNAs (No. = 1135) and human 
(No. = 1928) miRNAs spotted on the microarray used. 
A remarkable overlap was observed (Fig. 2S).  
Comparison of individual miRNAs in organs 
and body fluids of sham-exposed mice and 
MCS-exposed mice 
As to individual miRNAs, we evaluated by 
volcano-plot analysis (Fig. 3S) the miRNAs that were 
significantly dysregulated in mice exposed to MCS 
compared to sham-exposed mice. Table S1 shows the 
results, in terms of MCS/Sham fold ratio, of all 
miRNAs out of the 1135 miRNAs tested that were 
either upregulated or downregulated by MCS in the 
10 organs and 3 body fluids examined. 
 
 
Figure 1. Hierarchical cluster analysis (HCA) of miRNA profiles. HCA compared the profiles of 1135 miRNAs in 10 organs and 3 body fluids of mice aged 4 months, 
either sham-exposed (left panel) or exposed whole-body to MCS for 8 weeks (middle panel). The right panel was generated by calculating the difference between 
MCS and Sham values. 







Figure 2. Bidimensional principal component analysis (PCA) of miRNA 
profiles. PCA compared the profiles of 1135 miRNAs in 10 organs and 3 body 
fluids from mice aged 4 months, either sham-exposed (upper panel) or exposed 
whole-body to MCS for 8 weeks (middle panel). The bottom panel was 
generated by calculating the difference between MCS and Sham. The 
contributions to variance in Sham were 40.7% for PCA1 (X axis), 26.1% for 
PCA2 (Y axis), and 4.9% for PCA3 (not shown), whereas the contributions to 
variance in MCS were 39.2% for PCA1, 27.9% for PCA2, and 5.3% for PCA3 
(not shown). 
  
Based on the data reported in Table S1, we drew 
a figure (Fig. 4) showing the number of miRNAs that 
were significantly upregulated or downregulated by 
MCS in each organ and body fluid. The rank was as 
follows: lung 208 dysregulated miRNAs (18.3% of the 
1135 analyzed miRNAs), skeletal muscle 180 (15.9%), 
liver 138 (12.2%), blood serum 109 (9.6%), kidney 96 
(8.5%), spleen 89 (7.8%), stomach 36 (3.2%), heart 33 
(2.9%), BALF 32 (2.8%), urine 27 (2.4%), urinary 
bladder 12 (1.1%), colon 5 (0.4%), and brain 0. As 
shown in Fig. 4, there was a fair balance between 
upregulated and downregulated miRNAs in liver 
(51.4% upregulated and 48.6% downregulated), 
skeletal muscle (55.0% and 45.0%), blood serum 
(50.5% and 49.5%), kidney (51.0% and 49.0%), heart 
(51.5% and 48.5%), and BALF (46.9% and 53.1%). 
There was a prevalence of upregulated over down-
regulated miRNAs in stomach (63.9% vs. 36.1%), 
whereas downregulation was prevalent in spleen 
(62.9% downregulated and 37.1% upregulated), urine 
(77.8% and 22.2%) and, with sharp differences, in lung 
(91.3% and 8.7%). 
Common miRNA profiles in organs and body 
fluids  
A major problem in evaluating body fluid 
miRNAs as biomarkers in preventive medicine is to 
assess whether or not they reflect alterations occurr-
ing in target organs of carcinogens. To assess this, we 
determined by Venn Diagram analysis the contrib-
ution of the 10 body organs to the miRNA profiles of 
the 3 body fluids examined. Such an approach 
compares the list of miRNAs altered by MCS more 
than 2-fold in organs or fluids and indicates the 
number of those miRNAs that are common in both 
lists. The results of this analysis are shown in the pie 
charts reported in Fig. 5. The contribution of skeletal 
muscle to MCS-altered miRNAs detectable in blood 
serum was by far the highest as compared with other 
organs. In fact, 85 miRNAs were dysregulated both in 
skeletal muscle and blood serum, followed by liver 
and lung (40 each), kidney (36), spleen (26), heart (19), 
urinary bladder (3), colon and brain (both 0). In urine, 
the contribution of all examined organs was poor and 
no striking difference was detectable among different 
organs, although the contribution of kidney was the 
highest one. The situation was different in the BALF 
of MCS-exposed mice, in which the contribution of 
lung miRNAs was the most remarkable. Except for 
colon and brain, other organs gave some contribution 
as well.  
Another issue was the extent of miRNA overlap 
among the body fluids tested. As detected by 
comparative Venn Diagram analyses, there was 
limited overlap of miRNAs modulated by MCS in the 
3 body fluids. In particular, 11 miRNAs were 
modulated by MCS in both blood serum and BALF, 
and 13 miRNAs were modulated in both blood serum 
and urine. Four miRNAs were modulated in both 
BALF and urine (see Table S1).  
Fig. 6 shows the time course of miRNA profiles 
in the lung, blood serum, and urine of both 
sham-exposed and MCS-exposed mice after 2, 4, 6, 
and 8 weeks. In the lung, the effects of MCS on 
miRNA expression were mainly detectable after 8 
weeks of treatment. A similar situation was observed 
in blood serum, although the differences among 
different time points were less evident. All differences 
were attenuated in urine, but the effects of MCS were 
clearly detectable after 4 weeks.  







Figure 3. Comparative scatter plot analyses (SPA) of miRNA profiles. SPA evaluated the organotropism of MCS in modulating the profiles of 1135 miRNAs in 10 
organs and 3 body fluids from mice aged 4 months, either sham-exposed (Y axis) or exposed whole-body to MCS for 8 weeks (X axis). Each dot represents a miRNA, 
whose expression intensity can be inferred from the position in the X and Y axes, according to a color scale (blue, low; yellow, medium; orange to red, high). Dots 
falling outside the diagonal two-fold variation interval (diagonal green lines) correspond to miRNAs that were dysregulated more than two-fold in their expression by 
MCS. Upregulated miRNAs are located in the lower-right area and downregulated miRNAs are in the upper-left area. 






Figure 4. Organotropism of miRNAs in MCS-exposed mice. The values indicate the numbers of miRNAs that were either downregulated or upregulated by MCS in 




Figure 5. Contribution of 10 organs to the miRNA profiles of 3 body fluids 
from mice exposed whole-body to MCS for 8 weeks. The size of circles refers 
to the numbers of miRNAs that were significantly altered by MCS in their 
expression both in the indicated organ (Y axis) and body fluid (X axis). The 
reported values refer to the numbers of miRNAs that were either upregulated 
(blue portions) or downregulated (orange portions) both in the indicated organ 
and body fluid. 
 
Validation of microarray data by qPCR analysis 
Three miRNAs (let-7e, miR-125b, and miR-322- 
3p), all of them significantly dysregulated in selected 
organs of MCS-exposed mice as assessed by 
microarray, were further evaluated by qPCR. A total 
of 22 samples collected from both male and female 
mice were analyzed in parallel by means of the two 
techniques. The results, expressed in terms of MCS/ 
Sham ratios, are summarized in Table 1. In general, 
the results of qPCR analyses confirmed the trends 
(either downregulation or upregulation) generated by 
microarray analyses. Five samples only (let-7e in the 
heart of both males and females and in the spleen of 
males; miR-125b in the heart of males; and 
miR-322-3p in the lung and skeletal muscle of 
females) did not attain the statistical significance 
threshold of the MCS/Sham ratio when analyzed by 
qPCR. Microarray data were well correlated with 
qPCR data (r = 0.864, P < 0.01), with a regression 
equation of y = 0.52 + 0.832x, where x is microarray 
data and y is qPCR data. 
 
Table 1. Comparative evaluation by microarray and qPCR 
analyses of 3 miRNAs in organs of mice of both genders exposed 
to MCS. The results are expressed as MCS/Sham ratios. 
 let -7e  miR-125b  miR-322-3p 
Organ Gender microarray  qPCR  microarray  qPCR  microarray  qPCR 
Lung Males 0.45* 0.11*  0.41* 0.32*  0.44*  0.22* 
Females 0.27* 0.69*  0.38* 0.29*  0.52*  0.81 
          
Heart Males 0.67* 0.93  2.24* 1.51     
Females 0.31* 1.07  2.01* 2.27*    
          
Spleen Males 0.31* 0.73  7.08* 7.64*    
Females 0.38* 0.42*   4.42* 8.32*    
          
Muscle Males    3.94* 3.46*  2.63*  5.33* 
Females    6.41* 6.61*  2.41*  1.69 
          
Liver Males    5.50* 2.09*    
Females    9.84* 7.14*    
          
Kidney Males    9.36* 7.06*    
Females    5.40* 7.11*    
* P < 0.05, MCS vs. Sham  
 






Figure 6. Time-course modulation of miRNA profiles. The lines show the 
profiles of 1135 miRNAs in the lung, blood serum, and urines from mice aged 4 
months, either sham-exposed (panels on the left) or exposed whole-body to 
MCS (panels on the right) for either 2, 4, 6, or 8 weeks. The cluster of the 
miRNAs that were most strikingly modulated by MCS are highlighted in white. 
 
The differences between males and females for 
the analyzed samples were not statistically significant 
and consistently showed the same dysregulation 
trends. In particular, the means ± SE of MCS/Sham 
ratios evaluated by microarray for the 6 samples 
showing upregulation were 5.1 ± 1.12 in males and 5.1 
± 1.18 in females; for the 6 samples showing 
downregulation they were 0.5 ± 0.06 in males and 0.4 
± 0.04 in females. Those evaluated by qPCR for the 6 
samples showing upregulation were 4.5 ± 1.05 in 
males and 5.5 ± 1.15 in females; for the 5 samples 
showing downregulation they were 0.4 ± 0.11 in males 
and 0.7 ± 0.14 in females. 
Discussion 
Goals and limitations of the study 
The present study evaluated the expression 
profiles of 1135 miRNAs in 10 organs and 3 body 
fluids of mice, either under physiological conditions 
or following exposure to MCS for up to 8 weeks. The 
herein described results highlighted the multiorgan 
miRNA distribution as assessed in a single 
comparative experiment and, above all, at an 
exposure time when no MCS-related histopatholo-
gical alterations are apparent. However, at this stage, 
early molecular changes can be detected as MCS- 
related increases of both bulky DNA adducts and 
oxidative DNA damage in the lung [13]. In addition, 
as shown in this study, miRNA expression analysis 
was able to identify the target organs of MCS-related 
molecular damage. An obvious limitation of the study 
is that all organs are composed of multiple tissues and 
cell types that may provide differential contributions 
to the overall miRNA profile of each of them. For 
instance, within the respiratory tract, nucleotide 
alterations have been shown to be higher in both 
tracheal epithelium and BAL cells of rats exposed to 
environmental CS (ECS) as compared to whole lung 
[14]. In any case, since the lung tissue used in the 
present study was obtained from lavaged mice, BAL 
cells were absent in the lung samples examined. This 
whole-organ approach does not exclude any tissue 
compartment, thus providing a comprehensive 
evaluation of the overall contribution of each organ to 
miRNA body fluids. A further goal of the present 
study was to ascertain the extent of miRNA release 
from the analyzed organs into 3 body fluids in order 
to predict the translatability of miRNA analysis as a 
molecular tool for human biomonitoring. 
Predictivity of early miRNA alterations 
induced by MCS and pathological 
consequences 
 Evaluation of miRNAs under basal conditions 
showed that organs belonging to the same system or 
sharing a similar histological structure had matching 
overall expression profiles. In MCS-exposed mice, 
there were variable miRNA response patterns 
depending on the organ. For instance, consistent with 
previous studies in both rats [15, 16] and mice [9, 
17-19] exposed either to MCS or to ECS, 
downregulation of miRNA expression was by far 
most prevalent in the lung. Downregulation of 
miRNAs in the lung correlates with an upregulation 
of proteins targeted by the altered miRNAs, which 
reflects an attempt to defend the respiratory tract by 
triggering a variety of protective mechanisms, such as 
antioxidant pathways, detoxification of carcinogens, 
DNA repair, anti-inflammatory pathways, apoptosis, 
etc. However, a long-lasting exposure to CS causes 
irreversible miRNA alterations that activate toxic and 
carcinogenic mechanisms, such as modulation of 





oncogenes and oncosuppressor genes, cell proliferat-
ion, recruitment of undifferentiated stem cells, 
inflammation, inhibition of intercellular communic-
ation, angiogenesis, invasion, and metastasis [20]. In 
addition, at least when exposure starts soon after 
birth, in the medium term (7-9 months) MCS induces 
a significant increase in several histopathological 
alterations, malignant tumors among them [reviewed 
in ref. 21]. 
In addition, exposure of mice to MCS caused, 
after 7-9 months, kidney tubular epithelial 
hyperplasia and adenomas as well as epithelial 
hyperplasia and papillomas in the urinary bladder, 
whose increase was statistically significant in some 
studies [21]. In the present study, kidney and urinary 
bladder miRNAs exhibited similar global expression 
profiles in sham-exposed mice. However, the kidney 
reacted to MCS more intensely than the bladder and 
exhibited both upregulation and downregulation of 
miRNAs. It is noteworthy that the kidney was the 
main source of MCS-dysregulated miRNAs in urine 
and gave an appreciable contribution to blood serum 
miRNAs as well. This conclusion is consistent with 
the notion that several miRNAs are detectable in 
kidneys, where they are crucial for renal development 
and normal physiological functions and contribute 
significantly to the pathogenesis of renal disorders 
[22]. On the other hand, the alterations of miRNAs in 
the urinary bladder of MCS-exposed mice were 
poorly detectable in all examined biological fluids. It 
is noteworthy that the urine of smoking humans 
invariably contains mutagenic substances [23], but in 
the present study no important early miRNA 
alterations were detected in the bladder of 
MCS-exposed mice. This apparent discrepancy is 
presumably due to the fact that miRNAs were 
analyzed in the bladder as an organ in toto, rather than 
in the isolated bladder epithelium, and to the 
circumstance that mutagenic metabolites eliminated 
with the urine are formed in upstream organs, such as 
liver and lungs. 
Mixed miRNA alterations also occurred in other 
organs of the mice exposed to MCS. The differential 
patterns of response of lung and liver in ECS-exposed 
mice had already been pointed out in a previous 
study in which the liver reacted to ECS exposure by 
activating an array of miRNA-related defensive and 
detoxifying activities [18]. These data correlate with 
the absence of DNA adducts in the liver of rodents 
exposed to either MCS [14] or ECS [24]. It is 
noteworthy that no tumors are detectable in the liver 
even after a medium-term exposure of mice to MCS, 
which on the other hand often causes hepatotoxicity 
[21]. miRNA upregulation prevailed in the stomach of 
MCS-exposed mice, and an appreciable proportion of 
dysregulated miRNAs were released into the 
bloodstream. Smoking is one of the risk factors for 
gastric cancer, and nicotine promotes gastric tumor 
growth. Treatment of human gastric cancer cells with 
nicotine altered the expression of some miRNAs, in 
particular by upregulating miR-16 and miR-21, which 
are targeted by the transcription factor NF-κB [25]. 
Other miRNAs, such as miR-1, miR-133 and miR-206, 
have been reported to play a key role in 
tumorigenesis, progression, invasion and metastasis 
of gastric cancer [26].  
Once more, we emphasize that our study 
evaluated miRNA profiles at an early stage of the 
carcinogenesis process. Accordingly, the observed 
effects are likely to be ascribed to dysregulation of 
miRNA expression by MCS rather than to 
pathological conditions triggered by this agent. In 
contrast with the stomach, MCS induced only slight 
variations in the miRNA expression profile in the 
colon, and no MCS-altered miRNA detected in this 
organ was found in any of the examined body fluids. 
Important alterations of miRNA profiles, especially in 
the sense of downregulation, occurred in the spleen of 
MCS-exposed mice and were clearly detectable by 
analyzing blood serum and urine. These alterations 
are likely to reflect the induction of inflammatory 
alterations in white pulp, accompanied by the 
entrapment of red blood cells altered by MCS 
exposure in red pulp as a consequence of hemoglobin 
monocarboxylation and lipid membrane 
peroxidation. In addition, spleen contains a 
remarkable leukocyte population, which may play a 
role in the systemic inflammation produced by MCS. 
Multiorgan dysregulation of miRNA 
expression induced by MCS 
As detailed in Table S1, dysregulation by MCS of 
some miRNAs selectively occurred in certain organs, 
whereas other miRNAs were dysregulated in 
multiple organs and body fluids, sometimes with 
opposite trends in organs and body fluids. To give a 
few examples, let-7e was downregulated in lung, 
heart, and spleen. Downregulation of members of the 
let-7 family in the lung has previously been reported 
in both mice exposed to MCS [17] and rats exposed to 
ECS [15]. It is noteworthy that members of this family, 
acting as tumor suppressor miRNAs, are typically 
downregulated in human lung cancer, whereas the 
oncomiRNA miR-21, which was downregulated in 
the lung of MCS-exposed mice, is upregulated in lung 
cancer [27]. miR-1a-1 was downregulated in lung, 
liver, kidney, spleen, and stomach, and was increased 
in the blood serum of MCS-exposed mice. Note that 
miR-1a was downregulated in urethane-induced 
pulmonary carcinogenesis in mice, but at the same 





time its levels were decreased in the blood serum [28]. 
The tumor suppressor miR-126, which was upregul-
ated in the liver and downregulated in the urinary 
bladder of MCS-exposed mice, is downregulated in 
gastric cancer [27]. Likewise, miR-22, a possible tumor 
suppressor whose downregulation was proposed as a 
diagnostic biomarker for gastric cancer [29], was 
downregulated by MCS in the stomach and 
additionally in liver, spleen, and blood serum. 
miR-24, whose upregulation was shown to inhibit 
proliferation, metastasis, and to induce apoptosis in 
bladder cancer cells [30], was downregulated by MCS 
in liver, skeletal muscle, kidney, and urinary bladder, 
and was significantly decreased in urine. Within the 
miR-125 family, which has diverse functions in 
different cell contexts [31], miR-125b-1 was 
upregulated by MCS in multiple organs, including 
liver, kidney, heart, skeletal muscle, and spleen, but 
its levels were decreased in both lung and blood 
serum. Some miRNAs were regulated by MCS with 
similar trends in various organs. For instance, 
miR-293 was upregulated in liver, kidney, spleen, 
urinary bladder, and skeletal muscle, and miR-335-5p 
was strongly upregulated in liver, kidney, and spleen. 
miR-466o was downregulated in liver, kidney, and 
spleen. miR-494 was strongly upregulated in liver, 
kidney, spleen, and skeletal muscle, and was 
increased in blood serum, whereas miR-331-5p, 
miR-344d-3, and miR-370 were downregulated in 
liver, kidney, and spleen. miR-154, a potential tumor 
suppressor in liver carcinogenesis [32], was 
upregulated in both liver and kidney. On the other 
hand, miR-155, an important regulator of inflamm-
ation promoting alcohol-induced steatohepatitis and 
fibrosis in vivo [33], was strongly downregulated in 
the liver, kidney, and spleen of MCS-exposed mice, 
while its levels were increased in blood serum. The 
opposite trend of MCS-induced dysregulation 
observed in blood serum and lung is in line with our 
previous finding obtained in similar experimental 
models [9]. These patterns are amenable to the 
alteration induced by MCS in the miRNA maturation 
machinery resulting in lack of production of mature 
miRNAs accompanied by upstream accumulation of 
miRNA precursors.  
Besides dysregulation of miRNAs in the lung of 
MCS-exposed mice, which may be involved in the 
pathogenesis of lung cancer and COPD, of special 
interest is dysregulation in striated muscles, with the 
heart and skeletal muscles displaying similar trends at 
a global analysis as well as at the level of some 
individual miRNAs. miR-206 was the most typical 
miRNA, among the canonical miRNAs detectable in 
striated muscles, called myomiRs, which was 
upregulated by MCS in the skeletal muscle of 
MCS-exposed mice. This miRNA and other miRNAs 
that were upregulated in the skeletal muscle of 
MCS-exposed mice, such as miR-182, are targeted to 
myocytes and modulate the physiology and 
pathology of these cells by altering gene expression 
[34]. miR-206, whose physiological expression 
significantly decreases in mouse quadriceps during 
the first 12 weeks of life [35], plays a role in promoting 
muscle differentiation and regeneration [36] and in 
repairing exercise-induced muscle injury [37]. 
Interestingly, miR-206 was upregulated also in the 
lung, liver, and stomach of MCS-exposed mice, 
whereas it was decreased in the kidney, blood serum, 
and BALF. Dysregulation of this miRNA plays a key 
role in tumorigenesis, progression, invasion, and 
metastasis of gastric cancer, a knowledge that might 
be exploited for the development of future 
miRNA-based interventions for preventing or treating 
this type of cancer [26]. miR-501 is a novel 
muscle-specific miRNA, which works as a regulator 
of myosin heavy chain during muscle regeneration 
and might serve as a novel serum biomarker for the 
activation of adult muscle stem cells [38]. This miRNA 
was significantly decreased in both skeletal muscle 
and blood serum of MCS-exposed mice. Another 
miRNA, miR-183, was upregulated in both heart and 
skeletal muscle of MCS-exposed mice, while it was 
downregulated in lung, liver, and spleen, and was 
decreased in blood serum, BALF, and urine. This 
miRNA is part of the regulatory network revealing 
the mechanism of inflammation in atrial fibrillation 
[39]. 
It has been argued that non-physiological 
expression of miRNAs may contribute to both 
development and progression of cardiovascular 
diseases [40]. As demonstrated in rats, heart and 
lungs are the organs where the highest levels of bulky 
DNA adducts are detectable following exposure to 
ECS, and these nucleotide alterations are more 
persistent in the heart, presumably because of the less 
efficient DNA repair capacities in this organ [14]. The 
clinical outcome of these molecular lesions depends 
on the rate of cell proliferation. Thus, alterations in the 
lung are correlated with the development of lung 
cancers and BPCO, while alterations in both heart and 
skeletal muscle hardly evolve into cancer, at least in 
adults, because these organs are composed of 
perennial cells, and proliferation is a condicio sine qua 
non for the growth of a neoplastic mass. In fact, both 
heart tumors and skeletal muscle tumors, such as 
rhabdomyosarcomas, mainly occur at a young age, 
when muscle cells are affected at prenatal or perinatal 
stages and are still replicating. On the other hand, it is 
likely that molecular alterations in heart and skeletal 
muscle may be involved in the pathogenesis of 





degenerative diseases, such as cardiomyopathies [41] 
and skeletal muscle atrophy [42, 43]. 
Together with the colon, the brain was the only 
organ in which exposure of adult mice to MCS 
resulted in minimal alterations of miRNA profiles, 
which were mainly oriented in the sense of 
upregulation. This conclusion contrasts with our 
previous finding that exposure to MCS of neonatal 
mice of the same strain used in the present study 
induced DNA damage and altered base-excision 
repair and tau levels in the brain [44]. Presumably, 
this discrepancy is amenable to the fact that there are 
differences in the blood-brain barrier (BBB) between 
newborns and adults. In fact, studies in rabbits have 
demonstrated that, although a selective BBB is 
operative at birth, considerably higher uptake rates 
for some compounds occur in newborns [45]. Brain 
endothelial miRNAs play critical roles in the 
regulation of BBB function under normal and 
neuroinflammatory conditions [46], and certain 
miRNAs, such as miR-143 [47] and miR-150 [48], 
increase the permeability of BBB. The fact that no 
MCS-dysregulated miRNA was detectable in any of 
the three examined biological fluids, besides the poor 
dysregulation of miRNAs in the brain of 
MCS-exposed mice, demonstrates that the BBB was 
not damaged by MCS in adult mice after 8 weeks of 
exposure. 
miRNA signatures in body fluids 
 The mechanisms underlying the release of 
miRNAs into body fluids are still a matter of 
discussion, having been ascribed either to cell death 
or to other cellular biological mechanisms [7], and 
some extracellular miRNA species might carry 
cell-cell signaling functions during various physiolog-
ical and pathological processes [49]. The body fluids 
examined in the present study had been deprived of 
their cellular components by centrifugation in order to 
assess the release of miRNAs by the organs into fluids 
without the possible confounding contribution of 
cells. miRNAs may be either free in body fluids or 
associated with fluid components, such as lipoprot-
eins and ribonucleoprotein complexes, or packaged 
within extracellular vesicles such as exosomes, 
apoptotic bodies, and microvesicles or exosomes, 
which provide RNase protection [7, 50]. In the present 
study, RNA was purified from body fluids in such a 
way to include all forms of extracellular miRNAs. It 
should be taken into account that the miRNAs found 
in urine are eliminated from the body, whereas those 
found in the bloodstream are either eliminated 
through emunctory organs or transmitted to distant 
organs. Those found in BALF are removed from the 
lower respiratory spaces via the mucociliary escalator 
and either eliminated from the body by expectoration 
or swallowed. Swallowed miRNAs are expected to 
contact the mucosae of the GI tract, thus being either 
detoxified by the liver or ultimately eliminated with 
feces.  
The herein reported results clearly show that the 
numbers of MCS-dysregulated miRNAs released into 
each one of the examined body fluids are affected by 
pharmacokinetic mechanisms. Thus, the miRNAs 
detectable in the BALF are mainly of pulmonary 
origin, and the kidney is the main source of miRNAs 
detectable in urine. The skeletal muscle gave a 
striking contribution to the presence of MCS-dysreg-
ulated miRNAs in the blood serum, which was much 
higher as compared to the contribution given by the 
lungs and other organs. The comparison of 
MCS-dysregulated miRNAs in the three examined 
body fluids reflected the direct physiological 
relationship between blood and urine and the lack of a 
direct relationship between urine and BALF. 
Time-course experiments showed that the effects of 
MCS on miRNA expression in lung and blood serum 
were mainly detectable after 8 weeks of exposure to 
MCS, whereas the effects in urine, albeit less striking, 
were clearly detectable after 4 weeks. The rapidity of 
excretion of miRNAs with urine correlates with the 
finding that the appearance of mutagenicity in 
smokers’ urine is very fast [23]. 
The massive release of circulating miRNAs from 
the skeletal muscle of MCS-exposed mice is 
attributable to the fact that the skeletal muscle mass is 
by far the greatest as compared to the mass of other 
organs, accounting for about 40% of the body mass in 
humans. Accordingly, the number of cells that release 
altered miRNAs is higher than that of other organs. 
miRNAs have been reported to control mitochondrial 
function and insulin signaling in skeletal muscle cells 
[51], and mitochondria are known to be particularly 
susceptible to MCS [52, 53]. Circulating miRNAs 
exhibit a potential role as mediators of the cross-talk 
between the skeletal muscle and other tissues/organs 
[51]. myomiRs regulate myoblast proliferation and 
differentiation [54]. In humans, circulating heart and 
muscle myomiRs increased to a great extent in 
advanced heart failure, in parallel with an increase of 
cardiac troponin I, which emphasizes the usefulness 
of measuring circulating miRNAs as biomarkers for 
heart injury [55]. Our finding that exposure to MCS 
results in an early and considerable dysregulation of 
miRNAs in the skeletal muscle, from where they are 
massively released into the bloodstream, is not 
surprising, because patients suffering from COPD, of 
which smoking is the most important risk factor, 
commonly suffer from skeletal muscle dysfunction. 
Interestingly, consistent with our experimental data, 





CS exposure may contribute to the development of 
skeletal muscle dysfunction even before overt 
pulmonary pathology [42]. Exposure to MCS caused 
skeletal muscle atrophy also in a mouse model of 
COPD [43] and upregulated several pathways of 
metabolic processes and tissue degradation in 
muscles [56]. Evaluation of circulating miRNAs in 
myotonic dystrophy patients suggested that miRNAs 
might be useful as humoral biomarkers of that muscle 
disease [57]. The poor correlation between early 
alterations of miRNA profiles in the lung and in the 
blood serum of MCS-exposed mice is in agreement 
with the results of a previous study in mice exposed 
to the same agent during the first 4 months of life and 
thereafter kept in filtered air for an additional 3.5 
months, when smoking-related lung tumors were 
detectable [9]. Likewise, it has been reported that 
miRNA signatures in plasma do not correspond with 
miRNA signatures in BAL samples of lung cancer 
patients [8] and that extracellular miRNAs in pooled 
BAL samples from cancer patients are differentially 
expressed as compared with samples from noncancer 
patients [6]. The stability of miRNAs in BAL samples 
after bronchoscopy is noteworthy [58]. Therefore, in 
spite of the fact that the collection of BALF is 
semi-invasive, the analysis of this fluid appears to be 
more appropriate to detect smoking-related miRNA 
alterations of pulmonary origin than analysis of blood 
serum and urine, where the contribution of lung is 
confounded by the release of miRNAs from other 
organs. These data are applicable for diagnostic 
purposes and mechanistic studies in humans, also 
because the miRNA specificity of human tissues is 
remarkably correlated with that of rodents [59]. In 
addition, the translatability of our results to humans is 
also warranted by the overlap of mouse and human 
miRNAs in the microarrays used. 
The comparison of microarray data and qPCR 
data did not show any significant differences between 
males and females, at least for the selected miRNAs 
and organs. In any case, evaluation of intergender 
differences was beyond the scope of the present 
study, and the distinctive miRNA response to MCS of 
mouse lung and blood serum had been investigated in 
our previous studies [9, 60]. 
Conclusions 
 The results obtained show that after just 8 weeks 
of exposure of mice to MCS, when no histopatho-
logical damage was apparent, miRNAs profiles were 
altered in many organs, where they are predictive of 
possible pathological consequences. The lungs, 
skeletal muscle, and kidneys were the most important 
sources of MCS-dysregulated miRNAs in the BALF, 
blood serum, and urine, respectively. These data 
should be taken into account in studies evaluating 
miRNA profiles in body fluids for diagnostic 
purposes and preventive medicine strategies. 
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